The European Commission has approved the use of ocriplasmin for treating vitreomacular traction (VMT) in the European Union.

The drug has been approved for treating VMT when it is associated with a macular hole with a diameter of 400 µm or less.
ThromboGenics will be paid €45 million by Alcon, a subsidiary unit of Novartis, with a similar payment to be made with the first sale of the drug. Around 250,000-300,000 patients in Europe are reported to suffer from VMT with the current treatment involving a ‘watchful process’ until the patient is eligible for surgery.
Source-Medindia